Trajectories of Depressive Symptoms Among a Population of HIV-Infected Men and Women in Routine HIV Care in the United States
Depressive symptoms vary in severity and chronicity. We used group-based trajectory models to describe trajectories of depressive symptoms (measured using the Patient Health Questionnaire-9) and predictors of trajectory group membership among 1493 HIV-infected men (84%) and 292 HIV-infected women (16%). At baseline, 29% of women and 26% of men had depressive symptoms. Over a median of 30 months of follow-up, we identified four depressive symptom trajectories for women (labeled “low” [experienced by 56% of women], “mild/moderate” [24%], “improving” [14%], and “severe” [6%]) and five for men (“low” [61%], “mild/moderate” [14%], “rebounding” [5%], “improving” [13%], and “severe” [7%]). Baseline antidepressant prescription, panic symptoms, and prior mental health diagnoses were associated with more severe or dynamic depressive symptom trajectories. Nearly a quarter of participants experienced some depressive symptoms, highlighting the need for improved depression management. Addressing more severe or dynamic depressive symptom trajectories may require interventions that additionally address mental health comorbidities.
KeywordsDepression Depressive symptoms Trajectory analysis Group-based trajectory models HIV
The authors wish to thank the University of North Carolina at Chapel Hill Center for AIDS Research and National Institutes of Health [Grant Numbers R01MH100970, R24AI067039, P30 AI50410, L30MH110572, K99MH112413, and UL1TR001111], which supported this work. Dr. Bengtson was supported by a career development award from the National Institute of Mental Health [Grant Number K99MH112413].
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board at each CNICS site and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent to participate in the CNICS cohort was obtained from all individual participants included in the study.
Informed consent to participate in the CNICS cohort was obtained from all individual participants included in the study.
- 6.Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47(3):384–90.CrossRefPubMedGoogle Scholar
- 8.Ironson G, O’Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, et al. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med. 2005;67(6):1013–21.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.O’Cleirigh C, Newcomb ME, Mayer KH, Skeer M, Traeger L, Safren SA. Moderate levels of depression predict sexual transmission risk in HIV-infected MSM: a longitudinal analysis of data from six sites involved in a “prevention for positives” study. AIDS Behav. 2013;17(5):1764–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Tsai AC, Karasic DH, Hammer GP, Charlebois ED, Ragland K, Moss AR, et al. Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. Am J Public Health. 2013;103(2):308–15.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Watson LC, Amick HR, Gaynes BN, Brownley KA, Thaker S, Viswanathan M, et al. Practice-based interventions addressing concomitant depression and chronic medical conditions in the primary care setting: a systematic review and meta-analysis. J Prim Care Community Health. 2013;4(4):294–306.CrossRefPubMedGoogle Scholar
- 23.Kim MH, Mazenga AC, Devandra A, Ahmed S, Kazembe PN, Yu X, et al. Prevalence of depression and validation of the Beck Depression Inventory-II and the Children’s Depression Inventory-Short amongst HIV-positive adolescents in Malawi. J Int AIDS Soc. 2014;17:18965.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Choi SK, Boyle E, Cairney J, Collins EJ, Gardner S, Bacon J, et al. Prevalence, recurrence, and incidence of current depressive symptoms among people living with HIV in Ontario, Canada: results from the Ontario HIV Treatment Network Cohort Study. PLoS ONE. 2016;11(11):e0165816.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12(3):255–66.CrossRefPubMedGoogle Scholar
- 39.Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT, The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Care. Geneva, Switzerland: World Health Organization, Dependence DoMHaS; 2001.Google Scholar
- 42.Bengtson AM, Pence BW, Crane HM, Christopoulos K, Fredericksen RJ, Gaynes BN, et al. Disparities in Depressive symptoms and antidepressant treatment by gender and race/ethnicity among people living with HIV in the United States. PLoS ONE. 2016;11(8):e0160738.CrossRefPubMedPubMedCentralGoogle Scholar